Xiong Qianwei, Lin Houwei, Hua Xiaolin, Liu Li, Sun Ping, Zhao Zhen, Shen Xiaowei, Cui Daxiang, Xu Maosheng, Chen Fang, Geng Hongquan
1 Department of Pediatric Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, People's Republic of China .
Tissue Eng Part A. 2015 Jan;21(1-2):45-52. doi: 10.1089/ten.TEA.2013.0671. Epub 2014 Jul 25.
Macroscopic evidence of contracture has been identified as a major issue during the regeneration process. We hypothesize that lack of angiogenesis is the primary cause of contracture and explore a nanomedicine approach to achieve sustained release of vascular endothelial growth factor (VEGF) to stimulate angiogenesis. We evaluate the efficacy of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for long-term (3 months) sustained release of VEGF in bladder acellular matrix allografts (BAMA) in a swine model. We anticipate that the sustained release of VEGF could stimulate angiogenesis along the regeneration process and thereby inhibit contracture. Bladder was replaced with BAMA (5×5 cm), modified with PLGA NPs encapsulated with VEGF in a pig model. The time points chosen for sampling were 1, 2, 4, and 12 weeks. The regenerated areas were then measured to obtain the contracture rate, and the extent of revascularization was calculated using histological and morphological features. In the control group of animals, the bladder was replaced with only BAMA. The in vivo release of VEGF was evident for ∼3 months, achieving the goal of long-acting sustained release, and successfully promoted the regeneration of blood vessels and smooth muscle fibers. In addition, less collagen deposition was observed in the experimental group compared with control. Most importantly, the inhibition of contracture was highly significant, and the ultimate contracture rate decreased by ∼57% in the experimental group compared with control. In isolated strips analysis, there were no significant differences between BAMA-regenerated (either VEGF added or not) and autogenous bladder. BAMA modified with VEGF-loaded PLGA-NPs can sustainably release VEGF in vivo (>3 months) to stimulate angiogenesis leading to the inhibition of contracture. This is the first study to report a viable nanomedicine-based strategy to overcome contracture during bladder regeneration induced by BAMA. Furthermore, this study also confirms that insufficient angiogenesis plays a crucial role in the onset of contracture.
挛缩的宏观证据已被确定为再生过程中的一个主要问题。我们假设血管生成不足是挛缩的主要原因,并探索一种纳米药物方法来实现血管内皮生长因子(VEGF)的持续释放以刺激血管生成。我们评估聚乳酸 - 乙醇酸共聚物(PLGA)纳米颗粒(NPs)在猪模型的膀胱脱细胞基质同种异体移植物(BAMA)中对VEGF进行长期(3个月)持续释放的效果。我们预计VEGF的持续释放可以在再生过程中刺激血管生成,从而抑制挛缩。在猪模型中,用包裹有VEGF的PLGA NPs修饰的BAMA(5×5 cm)替换膀胱。选择用于取样的时间点为1、2、4和12周。然后测量再生区域以获得挛缩率,并使用组织学和形态学特征计算血管再生的程度。在动物对照组中,仅用BAMA替换膀胱。VEGF在体内的释放明显持续约3个月,达到了长效持续释放的目标,并成功促进了血管和平滑肌纤维的再生。此外,与对照组相比,实验组中观察到的胶原蛋白沉积较少。最重要的是,挛缩的抑制非常显著,与对照组相比,实验组的最终挛缩率降低了约57%。在离体条带分析中,BAMA再生的(添加或未添加VEGF)与自体膀胱之间没有显著差异。用负载VEGF的PLGA - NPs修饰的BAMA可以在体内持续释放VEGF(> 3个月)以刺激血管生成,从而抑制挛缩。这是第一项报道可行的基于纳米药物的策略来克服BAMA诱导的膀胱再生过程中挛缩的研究。此外,本研究还证实血管生成不足在挛缩的发生中起关键作用。